Stock & Company Details
Illumina Inc $ILMN
Price:
N/A
N/A
151M
$40B
52 Week High:
N/A
10 Day Average Volume:
N/A
49.18
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ILMN technical indicators
Latest Illumina Inc (ILMN) indicator readings as of 2026-10-09.
ILMN's 14-day RSI is 62.9, in neutral territory. At $278.17 it is trading 67.3% above its 200-day moving average of $166.27, and above its 50-day average of $226.92. Price sits in the middle of its Bollinger Bands ($215.85 to $300.54). ADX reads 42.0, indicating a trending market.
ILMN backtested strategy results
How 4 rule-based strategies performed on Illumina Inc (ILMN) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -36.7% | 28% | 18 | -73.6% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -1.1% | 32% | 25 | -53.9% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +49.0% | 55% | 22 | -31.0% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -23.5% | 57% | 30 | -58.0% |
Overview
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Finance Bot
Ask your questions
Start by typing a question below.
